Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP) (NCT03314207) | Clinical Trial Compass
CompletedNot Applicable
Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)
United States14 participantsStarted 2017-12-01
Plain-language summary
The purpose of this study is to evaluate subjects with X-linked retinitis pigmentosa caused by RPGR-ORF15 mutations in a clinical setting to fully characterize their condition, measure testing variability, and estimate rates of progression of clinical parameters.
Who can participate
Age range6 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male subjects with a clinical diagnosis of XLRP and a documented molecular diagnosis from a CLIA-certified laboratory of mutation within the ORF15 exon of the RPGR gene;
* At least 6 years of age;
* Willing and able to perform study procedures;
* Signed informed consent(s) obtained (and child assent where applicable).
Exclusion Criteria:
* Pre-existing eye conditions that would interfere with interpretation of study endpoints (e.g. glaucoma, corneal or lenticular opacities, diabetic retinopathy, history of retinal detachment);
* Participating in an interventional research study of drugs or devices for treatment of XLRP or other retinal diseases;
* Monoocular participants
* Any condition which leads the investigator to believe that the participant cannot comply with the protocol requirements or that may place the participant at an unacceptable risk for participation.